RUNX1 and Myelodysplasia: Presently, however, the 2022 International Consensus Classification (ICC) system categorizes AML with RUNX1 mutations under AML-myelodysplasia-related (MR), whereas the fifth edition of the World Health Organization (WHO) classification does not make this recognition [1,5].